ESPERION Announces Plan for Transformative Long-Term Growth

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. JBHT
3. CRWV
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. USB
10. SPY

Go back to ESPERION Announces Plan for Transformative Long-Term Growth

Credit Suisse Downgrades Esperion Therapeutics (ESPR) to Neutral

October 18, 2021 6:08 PM EDT

Credit Suisse analyst Judah Frommer downgraded Esperion Therapeutics (NASDAQ: ESPR) from to Neutral with a price target of $11.00 (from $28.00).

The analyst comments "Following a challenged launch for bempedoic acid during the Covid-19 pandemic, along with administrative complications borne out of preauthorization requirements for many prescriptions, Esperion communicated a shift in strategy to... More